



Date: 14<sup>th</sup> February, 2025

To,  
The Manager,  
Department of Corporate Services,  
BSE Limited  
P. J. Towers, Dalal Street,  
Fort, Mumbai – 400 001  
BSE Scrip Code: 533573

To,  
The Manager,  
Listing Department,  
National Stock Exchange of India Ltd.  
'Exchange Plaza', Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
NSE Symbol: APLLTD

Dear Sir / Madam,

**Sub: Alembic Pharmaceuticals Limited receives Establishment Inspection Report (EIR) for its Solid Oral Formulation Facility (F-4) at Jarod.**

**Ref.: Our earlier intimation dated 23<sup>rd</sup> November, 2024 - USFDA inspection at Alembic Pharmaceuticals Limited' Solid Oral Formulation Facility (F-4) at Jarod.**

We would like to inform the exchange that the Company has received Establishment Inspection Report (EIR) today with classification as "Voluntary Action Indicated (VAI)" for the inspection carried out by US Food and Drug Administration (USFDA) at our Solid Oral Formulation Facility (F-4) at Jarod, Vadodara. The inspection was conducted from 14<sup>th</sup> November, 2024 to 22<sup>nd</sup> November, 2024.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,  
**For Alembic Pharmaceuticals Limited**

**Manisha Saraf**  
**Company Secretary**

**ALEMBIC PHARMACEUTICALS LIMITED**

REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. • TEL: (0265) 2280550, 2280880 • FAX: (0265) 2281229  
Website : [www.alembicpharmaceuticals.com](http://www.alembicpharmaceuticals.com) • E-mail : [alembic@alembic.co.in](mailto:alembic@alembic.co.in) • CIN : L24230GJ2010PLC061123